Form 4 Filing for Cytek Biosciences, Inc.

This filing details transactions by Jiang Wenbin, President and CEO of Cytek Biosciences, Inc., on August 18, 2026. Wenbin acquired 11,781 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) with a transaction code "M" (as reported in the derivative table), and simultaneously disposed of 2,869 shares of Common Stock to cover tax withholding obligations, with a transaction code "F". Similar transactions occurred with larger RSU grants and subsequent tax withholdings throughout the day. Specifically, Wenbin acquired 22,100 RSUs and disposed of 5,382 shares for taxes; acquired 29,002 RSUs and disposed of 7,062 shares for taxes; and acquired 57,212 RSUs and disposed of 20,956 shares for taxes. All RSU transactions are reported with a share price of 0.00, indicating they are part of equity compensation. The disposal transactions for tax withholding were executed at a price of 4.67 per share.